Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting
Yagya Ahlawat, Heng Jiang, Delong Liu · 2026
Read Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting by Yagya Ahlawat, Heng Jiang, Delong Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13267412.txt.
Description
Yagya Ahlawat, Heng Jiang, and Delong Liu sum up 2026 updates on two drugs for myelodysplastic syndromes. These are marrow disorders where blood cell making fails, causing anemia. The updates come from work shared at the 2025 meeting of the American Society of Hematology. One drug, luspatercept, helps young red cells mature; the other, imetelstat, blocks an enzyme cancer cells use to keep dividing.
New analyses covered real-world use of luspatercept in lower-risk disease, including patients who had never had standard hormone-like shots. Imetelstat studies covered patients who depend on transfusions and those with advanced disease after other drugs failed. In one comparison, luspatercept freed more patients from transfusions than the standard shot, for longer. The authors map where each drug now fits in care.
Catalog record
| CREATOR | Yagya Ahlawat, Heng Jiang, Delong Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16520 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |